Description

PT 141 Sublingual Tablets

Introduction

PT 141 Sublingual Tablets represent a research product exclusively intended for scientific investigations and laboratory studies. With its unique characteristics and wide range of applications, PT-141 has become a valuable asset for researchers seeking to understand and address complex physiological and behavioral processes.

Key Characteristics

Containing a purified form of PT-141, these tablets are designed for controlled laboratory experiments, offering researchers a platform to explore the effects of this synthetic peptide on various physiological parameters.

Research Applications

The primary focus of research using PT 141 Tablets centers on understanding the potential impact of PT-141 on sexual desire in both female and male subjects, as well as its relevance to addressing erectile dysfunction.

Research Benefits

PT 141 and Potential Sexual Desire in Female Subjects

Research studies have suggested that PT-141 may have potential implications in enhancing sexual desire in female subjects. Investigations aim to elucidate the underlying mechanisms and potential applications in the context of female sexual function.

PT 141 and Erectile Dysfunction

Preliminary research has shown promise in the potential application of PT-141 for addressing erectile dysfunction. Studies aim to further elucidate the mechanisms involved and evaluate the efficacy of PT-141 in mitigating erectile dysfunction.

PT 141 and Potential Sexual Desire in Male Subjects

Studies have explored the impact of PT-141 on sexual desire in male subjects, indicating potential benefits in this area. Researchers are actively investigating the mechanisms and applications of PT-141 to address sexual dysfunction in men.

Summary

PT 141 Tablets offer a controlled and specialized tool for researchers to delve into the potential benefits of PT-141, specifically in the realms of sexual desire in both female and male subjects, as well as its relevance to addressing erectile dysfunction. These studies contribute to the growing body of knowledge surrounding synthetic peptides and their potential applications in the field of sexual health research.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Diamond, L., Earle, D., Rosen, R. et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 16, 51–59 (2004). https://doi.org/10.1038/sj.ijir.3901139 [Read More]
2. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006 Jul;3(4):628-638. doi: 10.1111/j.1743-6109.2006.00268.x. PMID: 16839319. [Read More]
3. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003 Jun;994:96-102. doi: 10.1111/j.1749-6632.2003.tb03167.x. PMID: 12851303. [Read More]